BAXTER INTERNATIONAL INC. Consolidated Statements of Income Twelve Months Ended December 31, 2014 and 2013 (unaudited) (in millions, except per share and percentage data)

	Twelve Months Ended December 31,		
	2014	2013	Change
NET SALES	\$16,671	\$14,967	11%
COST OF SALES	8,514	7,495	14%
GROSS MARGIN	8,157	7,472	9%
% of Net Sales	48.9%	49.9%	(1 pts)
MARKETING AND ADMINISTRATIVE EXPENSES % of Net Sales	4,029 24.2%	3,642 24.3%	11% (0.1 pts)
RESEARCH AND DEVELOPMENT EXPENSES	1,421	1,165	22%
% of Net Sales	8.5%	7.8%	0.7 pts
NET INTEREST EXPENSE	145	128	13%
OTHER EXPENSE (INCOME), NET	123	(9)	N/M
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	2,439	2,546	(4%)
INCOME TAX EXPENSE	493	534	(8%)
% of Income from Continuing Operations before Income Taxes	20.2%	21.0%	(0.8 pts)
INCOME FROM CONTINUING OPERATIONS	1,946	2,012	(3%)
INCOME FROM DISCONTINUED OPERATIONS, NET OF TAX ^A	551	0	N/M
	\$2,497	\$2,012	24%
INCOME FROM CONTINUING OPERATIONS PER COMMON SHARE			
Basic	\$3.59	\$3.70	(3%)
Diluted	\$3.56	\$3.66	(3%)
INCOME FROM DISCONTINUED OPERATIONS PER COMMON SHARE			
Basic	\$1.02	\$0.00	N/M
Diluted	\$1.00	\$0.00	N/M
NET INCOME PER COMMON SHARE			
Basic	\$4.61	\$3.70	25%
Diluted	\$4.56	\$3.66	25%
WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING			
Basic	542 547	543	
Diluted	547	549	
ADJUSTED PRE-TAX INCOME FROM CONTINUING OPERATIONS (excluding special items)	\$3,427 ^B	\$3,319 ^B	3%
ADJUSTED INCOME FROM CONTINUING OPERATIONS (excluding special items)	\$2,683 ^B	\$2,577 ^B	4%
ADJUSTED DILUTED EPS FROM CONTINUING OPERATIONS (excluding special items)	\$4.90 ^B	\$4.69 ^B	4%

A Operating results from the company's vaccines franchise are classified as discontinued operations for all periods presented.

^B Refer to page 11 for a description of the adjustments and a reconciliation to GAAP measures.